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OBJECTIVES: Glucagon-like peptide-1 (GLP-1) receptor agonists are indicated to
improve glycemic control in adults with Type 2 diabetes mellitus. The maximum
daily licensed dosages in the UK are 20g and 1.8mg for exenatide and liraglutide
respectively. In addition to factors such as glycaemic control, cost is an important
consideration when selecting treatments. The aim of this analysis was to describe
the real-world daily usage and cost of exenatide BID and liraglutide in the UK
setting. METHODS: Data and study period: UK records between October 2008 and
March 2011 from the IMS Dynamic Prescription database. This database captures
data from pharmacy records (45% national coverage) of actual prescriptions dis-
pensed, linked to individual patients (anonymised). Inclusion criteria: patients
have filled a prescription for a GLP-1 receptor agonist at least twice during the study
period; all key prescription fields are complete. The weighted average daily usage
was calculated for each agent using the total volume of product dispensed and the
number of patients filling prescriptions per month. Drug costs (British National
Formulary 61, 2011) were applied to estimate average daily cost (ADC). Key assump-
tions: patients are not stockpiling or disposing of drug; each prescription equals
one pack; patients are filling their prescriptions at the same pharmacy. RESULTS:
Data was available for a total number of unique patients of 19,200 and 12,690 for
exenatide BID and liraglutide (data available from July 2009) respectively. The av-
erage daily usage during the investigated time period was estimated to be 20.49g
for exenatide and 1.51mg for liraglutide, with an estimated ADC of £2.53 and £3.29
respectively. CONCLUSIONS: Based on the data described, GLP-1 receptor agonists
are being dispensed in amounts within an acceptable range of the maximum daily
licensed dosage. The ADC appears to be 30% higher for liraglutide with an esti-
mated additional daily spend of £0.76.
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OBJECTIVES: To estimate the average annual cost of treating patients with type 2
diabetes mellitus with insulin including: the cost of insulin, test strips for self-
monitoring of blood glucose levels, and additional healthcare professional (HCP)
time spent with patients following insulin initiation. The secondary objective was
to describe insulin prescribing patterns in the UK. METHODS: For insulin and test
strip costs a retrospective analysis of 2009/10 UK patient-level data was undertaken
using Cegedim Strategic Data. Costs were applied using the BNF and MIMS. To
estimate HCP resource use, 100 HCPs were surveyed on the number of contacts
with insulin patients in the 3 years prior to and the 3 years post insulin initiation.
Costs were applied using PSSRU 2010. RESULTS: A projected 24.5 million insulin
items were prescribed to 400,000 patients, generating an estimated average annual
insulin cost of £393 per patient. Long-acting and biphasic insulins together ac-
counted for more than 75% of the total volume and costs of insulin prescribed;
intermediate acting insulins accounted for 6% and 4% of the volume and costs
respectively. A projected 4.5 million packs of test strips were prescribed to 360,000
patients, generating an estimated average annual cost of test strips of £180 per
patient. Contact time across all HCPs peaked in the year following insulin initia-
tion. There was an absolute increase of 8 contacts per patient in the 3 years post
insulin initiation, representing an additional cost of £103 per patient.
CONCLUSIONS: Insulin initiation increases the cost of care not only because of the
insulin costs, but because of the package of resources that insulin requires. The
estimated cost of insulin, insulin pens, needles and test strips is £609 per patient.
The analysis suggests divergence from the NICE Clinical Guidelines 87 recommen-
dation that first-line insulin therapy should be intermediate NPH insulin.
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OBJECTIVES: Long-acting somatostatin analogs (SSA) with product-specific formu-
lation and means of administration are injected periodically in acromegaly and
neuroendocrine tumor (NET) patients. The ready-to-use device Somatuline Auto-
gel/Depot® reduces drug administration time by 80%. Its prefilled syringe also
avoids the risk of clogging reported for octreotide LAR. A simple decision-analytic
model aimed at estimating cost savings due to these differences in administration
was developed for the UK, France and Germany. METHODS: The decision tree
simulated four scenarios for SSAs Somatuline Autogel/Depot® and Sandostatin
LAR®, injected by either hospital- or community-based nurses. Injection success
depended on clogging event occurrence. In the case of clogging, the first dose was
assumed to be lost and a second injection performed. Administration costs were
valued based on average hourly nurse wages in addition to country-specific retail
drug costs. Several simulations were run depending on the baseline risk of clog-
ging, administration time, and their respective relative reduction due to use of
Somatuline Autogel/Depot®. RESULTS: Costs per successful injection were less for
Somatuline Autogel/Depot®, ranging from EUR 13 to EUR 44, EUR 52 to EUR 150 and
EUR 107 to EUR 127 respectively for France, Germany and the UK. As the prices for
both long-acting SSAs were the same in France, cost savings came 100% from
differences other than drug prices. For Germany and UK, the proportions of savings
due to lower clogging and administration time was estimated around 32% and 20%,
respectively. Based on low and high country-specific patient cohort size estima-
tions for acromegaly and NETs, these costs savings per patient could lead to overall
annual savings up to one million euros for France, six million euros for Germany,
and four million euros for the UK. CONCLUSIONS: Widespread usage of the new
pre-filled Somatuline device for injection of SSA might lead to substantial savings
for healthcare providers across Europe.
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OBJECTIVES: Diabetic macular edema (DME) is an ophthalmological complication
of diabetes that may lead to visual impairment and blindness if left untreated, and
even despite treatment with the current standard of care, laser coagulation. Cur-
rently, an estimated 2% of diabetics suffer from DME with vision loss. The aim of
the study was to evaluate the cost-effectiveness of ranibizumab versus laser coag-
ulation in the treatment of visual impairment due to DME. METHODS: A cost-
effectiveness analysis was simulated using a Markov model adapted for Austria.
The model is based on the PHIII-RESTORE trial. Outcome measures were ‘Vision
Years’ and QALY. Costs are year 2010 values. Direct medical costs comprise all
treatment costs due to diabetic macular edema. The cost of blindness was incor-
porated using data from an Austrian cost-of-illness-analysis. The model time ho-
rizon was lifetime. The analysis was performed from the perspective of the Aus-
trian health care system according to the Austrian Guidelines for Health Economic
Evaluations. RESULTS: The model assumes 7 injections of ranibizumab in the first
year and 4 injections in the second year, as well as 2 treatments with laser coagu-
lation in the first year and one treatment in the second year. Lifetime costs amount
to €17,417 for ranibizumab and to €16,286 for laser coagulation. The ICER is €5354
(incremental QALYs gain with ranibizumab of 0.22). The number of vision years is
10.19 for ranibizumab and 8.57 for coagulation; the incremental cost per additional
vision year gained is €701. CONCLUSIONS: The study suggests that in Austria,
ranibizumab treatment for visual impairment resulting from DME is a cost-effec-
tive strategy versus the current standard of care, laser coagulation.
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OBJECTIVES: Saxagliptin (Onglyza®) and sitagliptin (Januvia®) are DPP-4 inhibitors
licensed for the treatment of T2DM. The two treatments have been investigated as
an add-on to metformin in an 18-week, non-inferiority, RCT in 801 patients with
T2DM who failed to achieve adequate glycaemic control on metformin alone. Re-
sults showed that the newer treatment, saxagliptin, was noninferior to sitagliptin,
with a similar tolerability profile. Saxagliptin has a lower acquisition price, hence
this analysis sought to assess cost effectiveness of saxagliptinmetformin versus
sitagliptinmetformin using a cost utility analysis (CUA) framework from a UK
healthcare perspective. METHODS: The CUA utilised a validated model using UK-
PDS risk equations to estimate long run micro/macro-vascular complications and
mortality over a 40 year time horizon. Clinical parameters in the model included
HbA1c levels for treatment effect, weight gain and incidence of hypoglycaemic
adverse events. Parameter estimates were obtained from a mixed treatment com-
parison (MTC) of saxagliptin and sitagliptin, which included the head-to-head
study. Treatment costs were based upon UK published list prices. Established costs
and disutilities associated with long-term diabetic outcomes were used, based
upon a UKPDS sub study. Univariate/probabalistic sensitivity analysis was
conducted. RESULTS: The annual drug cost per patient for saxagliptin was £411.93
versus £433.57 for sitagliptin. In the base case, total discounted healthcare costs
over the 40 year time horizon were £9,907 with saxagliptin and £10,035 with sita-
gliptin, with the same discounted QALY outcomes (10.49). Saxagliptin was there-
fore cost saving in the base case analysis. This finding was consistent across a
range of sensitivity analyses, with the exception of lower 95% credible intervals for
saxagliptin efficacy which resulted in a small incremental cost for saxagliptin (£29).
CONCLUSIONS: Saxagliptin and sitagliptin have been shown to have comparable
therapeutic profiles in a head-to-head study and MTC, but lower healthcare costs
driven by a 5% lower drug acquisition cost.
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OBJECTIVES: Clinical guidelines for diabetes management issued by Polish Diabe-
tes Association (PDA) describe therapeutical goals in patients with diabetes. The
aim of this analysis was to determine additional costs that may be incurred for
treatment along with PDA recommendations (as compared with current treatment
practice), so that the growth of treatment-related expenses would remain cost-
effective in Polish setting. METHODS: Two hypothetical patients were defined:
John and Peter, whose clinical characteristics correspond to those of newly diag-
nosed patients with diabetes mellitus type 2 (DM2) in Poland. Diabetes progression
was modelled assuming that John is treated in line with current clinical practice
and Peter is treated along with PDA recommendations (HbA1c, LDL, HDL, SBP are
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maintained within PDA-defined limits). Simulations were conducted in CORE dia-
betes model, which is a Markov model built on the base of published clinical trials
and encompasses over a dozen of diabetes complications. The model was exten-
sively validated and allows for reliable estimation of costs and outcomes associ-
ated with diabetes. Model inputs were adapted to Polish setting. Economic analysis
was conducted in lifetime horizon, costs and outcomes were discounted (5% and
3,5%, respectively). Cost acceptability threshold in Poland is 25 511 euro per QALY
gained. RESULTS: John’s QALY is 0,3 lower that QALY of Peter. Treatment of John’s
complications is 400 euro more expensive as compared to Peter. If willingness to
pay (WTP) equals to €7500 euro per QALY, yearly costs of Peter’s treatment may be
250 euro higher that John’s. If WTP is €15,000, Peter’s treatment may be €450 more
expensive that John’s and if WTP is €25,000 the difference in treatment costs may
be as high as 725 euro. CONCLUSIONS:DM2 treatment along with PDA recommen-
dations may be cost-effective provided additional costs do not exceed €725 per
year.
PDB41
THE COST-EFFECTIVENESS OF GETTING TO GLUCOSE, BLOOD PRESSURE, AND
LIPID GOALS IN PATIENTS NEWLY DIAGNOSED WITH TYPE 2 DIABETES
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INTRODUCTION: Good T2DM management requires not only good control of blood
glucose, but also blood pressure and serum lipid levels. Although data from the
Swedish National Diabetes Registry indicates that more patients have attained
recommended levels of these biomarkers over time, a sizable proportion fails to
meet all of these goals. OBJECTIVES: Assess the cost-effectiveness of intensifying
therapy to achieve Swedish-specific treatment goals for HbA1c, systolic blood pres-
sure (SBP), and LDL versus usual care for patients newly diagnosed with T2DM and
younger than fifty. METHODS: We used the Economic and Health Outcomes
(ECHO)-T2DM model, a Markov-based micro-simulation model, to simulate the
lifetimes of 500 cohorts of 500 hypothetical patients under two different scenarios:
1) treatment to maintain target goals for HbA1c, SBP and LDL; and 2) treatment to
maintain levels observed empirically in Sweden. Pharmacotherapy treatment
pathways for the control of hyperglycemia, hypertension and dyslipidemia fol-
lowed Swedish guidelines and were identical in the two scenarios. The costs of
pharmacotherapy and medical events were obtained from Swedish data.RESULTS:
Treatment to HbA1c, SBP and LDL goals versus treatment to observed levels in
Sweden resulted in a small QALY gain (0.13) and medical cost-savings of SEK
3552(€395). Spending on glucose-lowering agents, anti-hypertensives, and lipid-
lowering agents was increased by SEK 4136(€460), SEK 4864(€540) and SEK
2390(€265), respectively. Costs due to micro- and macrovascular complications
were reduced by SEK 5731(€637) and SEK 9522(€1058), respectively. CONCLUSIONS:
For patients newly diagnosed with T2DM and younger than fifty in Sweden, inten-
sifying therapy to maintain target glucose, blood pressure, and lipid levels resulted
in increased spending on pharmacotherapy, however, spending on micro- and
macrovascular events was reduced by a greater degree. These results suggest that
allocating more resources toward the attainment of these goals may be welfare-
improving.
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OBJECTIVES: To compare the cost-effectiveness of Follitropin Alpha (Gonal-F®),
which is a recombinant FSH, with a urinary highly purified hp-FSH (Menopur®)
used in assisted reproduction in Greece.METHODS:A decision tree in combination
with a Markov model was constructed to assess the clinical and economical impact
of comparators for three consecutives cycles. Transition probabilities for all stages
of a treatment cycle (i.e, cancelled ovum retrieval, successful recovery of oocytes
etc) were derived from literature and validated by clinical experts. Cost compo-
nents such as “initial treatment cost”, cost of “oocytes”, “oocyte pick-up”, “fertil-
ization”, “transfer”, “cryo preservation” and “frozen- thawed embryo transfer
(FET)” were derived from the electronic databases of selected private and public
clinics. The average number of units used per IVF and the rate of adverse events
were based on the literature. Drug prices and reimbursement tariffs, were obtained
from the “Government Gazette” and valued at 2011 prices. A probabilistic sensitiv-
ity analysis was performed to deal with uncertainty and to construct variability
measures. RESULTS: There was a statistically significant difference in favor of the
r-FSH arm compared to hp-HMG, which is associated with 52 more life births
(95%CI: 26-78, p-value0.001) per 1,000 patients. The cost per life birth was esti-
mated at €16,906 (95%CI: €16,347 – €17,516) and €17,286 (95%CI: €16,740 – €17,845) in
the r-FSH and hp-HMG arms, respectively. The cost per IVF was estimated at €4,365
(95%CI: €4,205 – €4,506) in the r-FSH and €3,815 (95%CI: €3,661 – €3,953) in hp-HMG
arm, indicating a difference at €550 (95%CI: €365 – €730, p-value0.001). The incre-
mental cost per life birth (ICER) for r-FSH versus hp-HMG was estimated at €14,540
(95%CI: €10,509 – €21,868), while the incremental cost per life year was estimated at
€4,153 (95%CI: €2,038 – €6,233). CONCLUSIONS: r-FSH may represent a cost-effec-
tive choice compared with a urinary hp-FSH (Menopur®) used for ovarian stimu-
lation in the Greek setting.
PDB43
THE ECONOMIC IMPACT OF WEIGHT LOSS IN PATIENTS NEWLY DIAGNOSED
WITH TYPE 2 DIABETES MELLITUS (T2DM) AND YOUNGER THAN FIFTY IN
SWEDEN
Willis M1, Neslusan C2, He J2, Worbes-Cerezo M3
1IHE, Lund, Sweden, 2Janssen Global Services LLC, raritan, NJ, USA, 3Janssen-Cilag S.A., Madrid,
Spain
OBJECTIVES: This study estimated the effect of weight reduction on long-term
outcomes and associated direct medical costs for patients newly diagnosed with
T2DM and less than fifty years old in Sweden. METHODS: We simulated the life-
times of 500 cohorts of 1000 patients with characteristics based on the Swedish
National Diabetes Register using the Economic and Health Outcomes (ECHO)-T2DM
model. All patients were assumed to increase weight over time (0.23 kg per year)
however, half of the patients were assumed to lose 5 kg in the first year, so that a 5
kg differential was maintained. The effect of weight on T2DM complications was
modeled using risk equations from the UK Prospective Diabetes Study, wherein
weight is only a direct determinant of the risk of congestive heart failure (CHF). The
risks of stroke and myocardial infarction are affected only indirectly via their link-
age with CHF, and mortality risk is affected only indirectly via macrovascular event
history. Weight change was assumed to impact QALYs by an amount reported in
the T2DM-specific CODE-2 study. Pharmacotherapy was administered according to
Swedish recommendations and Swedish cost data was used for medical events and
pharmacotherapy. RESULTS: A weight loss of 5 kg resulted in cost-savings of SEK
654 (€69) over an average of 17.1 years, mainly attributable to reductions in CHF
incidence. Life years increased marginally; QALYs, however, increased more sub-
stantially (0.18). CONCLUSIONS: At a relatively conservative willingness-to-pay
threshold of SEK 250,000 (€26,540), an intervention that resulted in a one-time
weight loss of 5 kg would be welfare improving at a cost of up to SEK 45,654 (€4,846)
over 17.1 years. As this simulation conservatively excluded a number of other
benefits of weight loss (e.g., effects via improved lipids, blood pressure and reduc-
tions in other weight-related illnesses), the true economic value is likely greater.
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OBJECTIVES: The aim of this economic evaluation was to test the hypothesis that
the clinical benefits observed with pioglitazone in the PROactive Study will lead to
economic benefits in terms of reduced macrovascular complications costs and
insulin treatment in Italy (the trial compared standard of care  pioglitazone ver-
sus standard of care alone).METHODS:Two analyses were undertaken; within trial
analysis and life-time simulation. The PROactive study provided the clinical and
resource utilization data to estimate the cost-effectiveness of pioglitazone in the
within trial analysis and was the basis for the secondary analysis which undertook
a life time simulation using a modified version of the validated CORE diabetes
model. CODE-II utility values were used for the base case. Due to the distribution
system of pioglitazone in Italy, two different prices were used; the public price paid
by the retail market (€2.11 per patient per day) and the ex-factory price discounted
by 25% (€ 0.96 per patient per day). Costs and health gains were discounted at the
joint rate of 3%. RESULTS: The incremental utility gain in within trial analyses was
0.0191, the incremental event and medication costs in the public price scenario
were €842 leading to an ICER of €43,996 per QALY. In the lifetime simulation model
the incremental utility gain was 0.149, the incremental event and medication costs
in the public price scenario were €3,783 leading to an ICER of €25,426 per QALY. In
the ex-factory price discounted by 25% scenario the medication costs were lower
leading to the inclusion of pioglitazone in treatment being dominant in both
analyses. CONCLUSIONS: In the Italian setting reduced costs for macrovascular
complications and insulin treatment leads to the inclusion of pioglitazone in treat-
ment being within standard cost-utility thresholds and is therefore an effective use
of health resources.
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OBJECTIVES: To estimate the long-term cost-effectiveness of transferring type 2
diabetes patients to an insulin detemir regimen therapy from a Neutral Protamine
Hagedorn (NPH) insulin regimen in the Portuguese routine clinical practice.
METHODS: A computer simulation model “CORE Diabetes Model” was used to
make long-term projections of clinical outcomes and direct medical costs based on
short term findings from the European cohort in the PREDICTIVE trial. Therapy
conversion to insulin detemir was associated with a reduction in glycosylated
haemoglobin (HbA1c) by 0.2% (p  0.05), mean body weight was reduced by 0.7 kg
(p0.01) and the incidence of total hypoglycaemia decreased from 11.7 to 3.0 epi-
sodes per patient/year (p  0.0001). Events were projected for a time horizon of 30
years. The cost analysis takes the perspective of the Portuguese National Health
System. RESULTS: Therapy conversion to insulin detemir plus OADs improves life
expectancy by 0.056 years and quality-adjusted life years (QALY) by 0.462 com-
pared to NPH insulin plus OAD. The incremental cost effectiveness ratio cost per
life years gained and per QALY gained with insulin detemir plus OADs treatment as
compared to NPH insulin plus OADs is 3,239€ and 393€ respectively. Type 2 diabetes
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